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Abstract
Dysregulated TNFR signalling is associated with many inflammatory disorders, including some forms of arthritis
and inflammatory bowel disease, and targeting TNF has been an effective therapeutic strategy in these
diseases and for cancer immunotherapy [4, 5, 38].
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This is a citation summary for Tumour necrosis factor (TNF) receptor family in the Guide to Pharmacology
database (GtoPdb). It exists purely as an adjunct to the database to facilitate the recognition of citations to and
from the database by citation analyzers. Readers will almost certainly want to visit the relevant sections of the
database which are given here under database links.
GtoPdb is an expert-driven guide to pharmacological targets and the substances that act on them. GtoPdb is a
reference work which is most usefully represented as an on-line database. As in any publication this work
should be appropriately cited, and the papers it cites should also be recognized. This document provides a
citation for the relevant parts of the database, and also provides a reference list for the research cited by those
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Please note that the database version for the citations given in GtoPdb are to the most recent preceding version
in which the family or its subfamilies and targets were substantially changed. The links below are to the current
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Database links
Tumour necrosis factor (TNF) receptor family
http://www.guidetopharmacology.org/GRAC/FamilyDisplayForward?familyId=334
    Receptors
            TNFR1(tumor necrosis factor receptor 1)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1870
            TNFR2(tumor necrosis factor receptor 2)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1871
            lymphotoxin β receptor
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1872
            OX40
1
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1873
            CD40
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1874
            Fas
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1875
            decoy receptor 3
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2322
            CD27
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1876
            CD30
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1877
            4-1BB
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1878
            DR4(death receptor 4)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1879
            DR5(death receptor 5)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1880
            decoy receptor 1
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2323
            decoy receptor 2
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2324
            RANK(receptor activator of NF-kappa B)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1881
            OPG(osteoprotegerin)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1882
            DR3(death receptor 3)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1883
            TWEAK receptor
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1884
            TACI
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1885
            BAFF-R(BAFF receptor)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1886
            HVEM(herpes virus entry mediator)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1887
            nerve growth factor receptor
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1888
            BCMA(B cell maturation antigen)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1889
            GITR(glucocorticoid-induced TNF receptor)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1890
            TAJ(toxicity and JNK inducer)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1891
            RELT
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1892
            DR6(death receptor 6)
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1893
            TNFRSF22
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1894
            TNFRSF23
2
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1895
            ectodysplasin A2 isoform receptor
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1896
            ectodysplasin 1, anhidrotic receptor
            http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2325
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